72 related articles for article (PubMed ID: 38637754)
1. Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective.
Takeshima T; Sakai F; Wang X; Yamato K; Kojima Y; Zhang Y; Bennison C; Simons MJHG
Pharmacoeconomics; 2024 Jul; 42(7):811-822. PubMed ID: 38771521
[TBL] [Abstract][Full Text] [Related]
2. A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy.
Wolters S; Carpay JA; Pronk MH; Zuurbier KWM; Driessen MT; Lyras L; Postma MJ
BMC Neurol; 2024 Jun; 24(1):214. PubMed ID: 38914929
[TBL] [Abstract][Full Text] [Related]
3. A real-world prospective observational study of eptinezumab in Asian patients with migraine.
Zhao YJ; Ong JJY; Sonu SK; Dang J; Ng CC; Herr KJ; Bose R; Jion YI
Headache; 2024 May; ():. PubMed ID: 38785386
[TBL] [Abstract][Full Text] [Related]
4. Eptinezumab for the treatment of migraine.
Spuntarelli V; Negro A; Luciani M; Bentivegna E; Martelletti P
Expert Opin Biol Ther; 2021 Aug; 21(8):999-1011. PubMed ID: 34009094
[TBL] [Abstract][Full Text] [Related]
5. Eptinezumab for the preventive treatment of migraine.
Villar-Martínez MD; Moreno-Ajona D; Goadsby PJ
Pain Manag; 2021 Mar; 11(2):113-121. PubMed ID: 33280422
[TBL] [Abstract][Full Text] [Related]
6. An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity.
Griffin E; Shirley G; Lee XY; Awad SF; Tyagi A; Goadsby PJ
J Headache Pain; 2024 Apr; 25(1):59. PubMed ID: 38637754
[TBL] [Abstract][Full Text] [Related]
7. Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial.
Ashina M; Tepper SJ; Gendolla A; Sperling B; Ettrup A; Josiassen MK; Starling AJ
J Headache Pain; 2023 Nov; 24(1):155. PubMed ID: 37985968
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
Ashina M; Lanteri-Minet M; Pozo-Rosich P; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
Lancet Neurol; 2022 Jul; 21(7):597-607. PubMed ID: 35716692
[TBL] [Abstract][Full Text] [Related]
9. Competing treatments for migraine: a headache for decision-makers.
Mistry H; Naghdi S; Underwood M; Duncan C; Madan J; Matharu M
J Headache Pain; 2023 Dec; 24(1):162. PubMed ID: 38053051
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
Ashina M; Lanteri-Minet M; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B; Pozo-Rosich P
Cephalalgia; 2023 May; 43(5):3331024231170807. PubMed ID: 37125484
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives.
Sussman M; Benner J; Neumann P; Menzin J
Cephalalgia; 2018 Sep; 38(10):1644-1657. PubMed ID: 30142988
[TBL] [Abstract][Full Text] [Related]
12. Preventive treatment patterns in the adult migraine population: an observational UK study over 7 years.
Kernick D; Kondori N; Pain A; Mount J; Appel C; Ranopa M; Gulati T
BMC Prim Care; 2024 Jan; 25(1):34. PubMed ID: 38262999
[TBL] [Abstract][Full Text] [Related]
13. Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial.
Jönsson L; Regnier SA; Kymes S; Awad SF; Talon B; Lee XY; Goadsby PJ
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):797-803. PubMed ID: 37256558
[TBL] [Abstract][Full Text] [Related]
14. Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures.
Goadsby PJ; Barbanti P; Lambru G; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
Eur J Neurol; 2023 Apr; 30(4):1089-1098. PubMed ID: 36583633
[TBL] [Abstract][Full Text] [Related]
15. Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study.
Barbanti P; Goadsby PJ; Lambru G; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
J Headache Pain; 2022 Dec; 23(1):153. PubMed ID: 36460983
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
